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Abstract 
Background: Despite the known risk of diabetes‑induced cardiac fibrosis, less is known about whether diabetes 
causes an altered cardiac phenotype independent of coronary atherosclerosis. Peroxisome proliferator‑activated 
receptor δ (PPARδ), a versatile regulator of metabolic homeostasis, may be a potential therapeutic target. Herein we 
investigated the effectiveness of telmisartan, a unique angiotensin receptor blocker that increases PPARδ expression, 
in improving left ventricular remodeling in diabetic humans and rats.
Methods: In this longitudinal, prospective study, we enrolled 15 diabetic patients receiving telmisartan (20 mg/day) 
for 12 weeks. After treatment, strain was measured and compared with the baseline value. Using streptozotocin to 
induce type 1 diabetes rat model, we measured PPARδ expression and downstream targets.
Results: After treatment with telmisartan, both longitudinal and circumferential strains improved in diabetic patients. 
Compared with that of controls, the diabetic rat heart developed significant fibrosis, which markedly decreased after 
treatment with telmisartan (30 mg/kg/day, orally) for 7 days. After incubation with 30 mM glucose, rat cardiomyocytes 
showed a significant down‑regulation of PPARδ. Interestingly, the increased expression of fibrosis‑associated proteins, 
including signal transducer and activator of transcription 3 (STAT3) was attenuated by the co‑incubation of GW0742, a 
PPARδ agonist. By knockdown or inhibition of STAT3, the hyperglycemia related high expression of fibrosis associated 
targets was reversed. Independent from the hyperglycemic incubation, STAT3 over‑expression led to similar results. 
Conversely, in the presence of GSK0660, a PPARδ inhibitor, the protective effects of telmisartan were diminished.
Conclusion: Telmisartan improved the hyperglycemia‑induced cardiac fibrosis through the PPARδ/STAT3 pathway.
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Background
The prevalence of diabetes has continued to increase, 
and its complications, including cardiac fibrosis-induced 
myocardial dysfunction and chronic heart failure, are 
threats to the health of millions of people [1, 2]. How-
ever, little is known about whether diabetes causes an 
altered cardiac phenotype independent of coronary 
atherosclerosis. To detect myocardial dysfunction at 
an early stage, instead of histological evidence, imag-
ing methods, such as speckle-tracking echocardiogra-
phy (STE), can be used to unmask subtle changes in the 
cardiac function of patients with systemic conditions 
[3]. Telmisartan, an angiotensin receptor blocker (ARB), 
lowers not only blood pressure but also insulin resist-
ance [4]. Different from other ARBs, telmisartan did not 
increase the incidence of diabetes and conversely, ame-
liorated atrial remodeling as well as reduced suscep-
tibility to atrial arrhythmia [5, 6]. In a study using STE, 
telmisartan was observed to have beneficial effects on 
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left ventricular (LV) structure in a hypertensive patient 
[7, 8]. More recently, it was also found to ameliorate LV-
remodeling in post-infracted or doxorubicin-induced 
cardiomyopathy by activating peroxisome proliferator-
activated receptors (PPARs) [9–12]. Among PPARs, 
PPARδ is widely observed in diabetic disorders, likely 
because cardiomyocyte-restricted PPARδ deletion causes 
cardiac hypertrophy [13–15]. Previous studies have indi-
cated that inhibitors of reactive oxygen species (ROS) 
production or mitogen-activated protein kinase (MAPK) 
activation are involved in the reduction of cardiac PPARδ 
expression in response to hyperglycemia in hepatocytes 
and adipocytes [16]. Signal transducer and activator of 
transcription 3 (STAT3), a pivotal mediator in cardiac 
hypertrophy, was also found to be involved in PPARβ/δ-
regulated insulin resistance in acute liver disease [17, 18]. 
Nevertheless, the mechanisms of improvement of cardiac 
remodeling through ARBs have not been fully elucidated 
in diabetic patients. In this study, we aimed to investigate 
the regulatory role of PPARδ in diabetes-induced cardiac 
fibrosis under telmisartan treatment.
Methods
Objective
Fifteen patients at the Chi-Mei Medical Center who were 
newly diagnosed with diabetes according to the definition 
of the World Health Organization were initially included 
between June 2014 and March 2015. In addition, 10 
age- and gender-matched controls were enrolled. The 
informed consent was obtained from each patient and 
the study was conducted according to the recommenda-
tions of the Declaration of 1975 Helsinki on Biomedical 
Research involving human subjects and was approved 
by the local Ethics Committee (IRB: 10307-003). Written 
informed consent was obtained from each participant. 
All participants underwent echocardiographic evaluation 
before and after 3 months of telmisartan therapy.
Echocardiography
Standard echocardiography was performed (Vivid E9; 
GE Vingmed Ultrasound AS, Horten, Norway) with a 
3.5-MHz multiphase-array probe in accordance with the 
recommendations of the American Society of Echocardi-
ography [19]. LV ejection fraction (LVEF) was measured 
using the biplane Simpson’s method. In addition, LV dias-
tolic function-associated parameters including isovolu-
mic contraction time (IVCT), isovolumic relaxation time 
(IVRT), ejection time (ET), deceleration time, transmitral 
and tricuspid early filling velocity (E) to atrial velocity (A) 
ratio were measured. Tissue Doppler imaging values of 
the right and left ventricles were obtained from the api-
cal four-chamber view using a sample volume placed at 
the lateral corner of the tricuspid annulus and anterior 
and lateral sections of the mitral annulus. Peak systolic 
annular velocity (S′) and early (e′) and late (a′) annular 
diastolic velocities were measured. In addition, myocar-
dial performance index, also known as the Tei index, was 
calculated as (IVCT + IVRT)/ET.
STE analysis for deformation
Standard apical four-chamber and short-axis views were 
recorded in digital loops for deformation analysis of the 
LV [3]. The images were acquired with frame rates of 
70–90 frames/s and stored for three cycles. The images 
were analyzed off-line using EchoPAC 9.0 computer 
software (GE-Vingmed Ultrasound AS). As described 
previously, we measured the LV peak systolic global lon-
gitudinal strain in the apical views. In addition, LV cir-
cumferential strain was also obtained from the short-axis 
view at the papillary muscle level.
Materials
GW0742 (a specific PPARδ agonist) and GSK0660 (a spe-
cific PPARδ antagonist) were purchased from Santa Cruz 
Biotechnology, Inc. (Santa Cruz, CA, USA). The antibod-
ies, including STAT3 and connective tissue growth factor 
(CTGF), were purchased from Abcam (Cambridge, MA, 
USA) and matrix metallopeptidase 9 (MMP9) was from 
Minipore.
Animals
Male Sprague–Dawley rats, weighing 200–250  g, were 
obtained from the Animal Center of National Cheng 
Kung University Medical College. All experiments were 
performed under anesthesia with 3  % isoflurane, and 
all efforts were made to minimize suffering. The animal 
experiments were approved and conducted in accord-
ance with local institutional guidelines for the care and 
use of laboratory animals in Chi-Mei Medical Center 
(No. 100052307) and conformed to the Guide for the 
Care and Use of Laboratory Animals. At the end of the 
experiments, hearts were excised from isoflurane-euth-
anized mice, washed in phosphate-buffered saline (PBS), 
fixed overnight in 4 % paraformaldehyde, and embedded 
in paraffin. After serial sectioning of hearts, 5-μm sec-
tions were stained with Masson trichrome for the quanti-
fication of myocardial fibrosis.
Streptozotocin (STZ)‑induced type 1‑like diabetic rats
Diabetic rats were induced by intravenously injecting 
STZ at 65 mg/kg (Sigma-Aldrich Inc., USA) into fasting 
rats as described previously. The animals were consid-
ered diabetic if they had a plasma glucose concentration 
over 350  mg/dL. Diabetic rats received either telmisar-
tan (30  mg/kg/day, orally) or metformin (100  mg/kg/
day, orally). To evaluate the role of PPARδ in the effects 
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of telmisartan, some rats were treated with the PPARδ 
antagonist GSK0660 (1  mg/kg/day, intraperitoneally) 
30 min before the telmisartan treatment. Each condition 
includes eight rats.
Cell cultures
H9C2 cells were used in the experiments after 3–4 days 
in culture. To mimic the hyperglycemic status, cells 
were incubation with 30 mM glucose for 24 h and then 
changed to a glucose free medium. In alternative groups, 
H9C2 cells were subsequently treated with GW0742 
(10−6 M) for 30  min, washed twice with PBS, and 
removed by trypsinization. The cells were then collected 
and subjected to a protein expression assay. Cells were 
additionally treated with GSK0660 (10−6 M) for 30  min 
before the GW0742 treatment.
Western blotting analysis
Protein was extracted from tissue homogenates and cell 
lysates using ice-cold radioimmunoprecipitation assay 
buffer supplemented with phosphatase and protease 
inhibitors (50  mM sodium vanadate, 0.5  mM phenyl-
methylsulfonyl fluoride, 2 mg/mL aprotinin, and 0.5 mg/
mL leupeptin). Protein concentrations were determined 
using a Bio-Rad protein assay (Bio-Rad Laboratories, 
Inc., Hercules, CA, USA). Total proteins (30  mg) were 
separated by sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (10  % acrylamide gel) using a Bio-Rad 
Mini-Protein II system. The protein was transferred to 
expanded polyvinylidene difluoride membranes (Pierce, 
Rockford, IL, USA) with a Bio-Rad Trans-Blot sys-
tem. After transfer, the membranes were washed with 
PBS and blocked for 1 h at room temperature with 5 % 
(w/v) skimmed milk powder in PBS. The manufacturer’s 
instructions were followed for the primary antibody reac-
tions. Blots were incubated overnight at 4  °C with an 
immunoglobulin-G polyclonal rabbit antimouse antibody 
(Affinity BioReagents, Inc., Golden, CO, USA) (1:500) in 
5 % (w/v) skimmed milk powder dissolved in PBS/Tween 
20 (0.5 % by volume) to bind the target proteins such as 
PPARδ. The blots were incubated with goat polyclonal 
antibody (1:1000) to bind the actin that served as the 
internal control. After the removal of the primary anti-
body, the blots were extensively washed with PBS/Tween 
20 and then incubated for 2 h at room temperature with 
the appropriate peroxidase-conjugated secondary anti-
body diluted in 5 % (w/v) skimmed milk powder and dis-
solved in PBS/Tween 20. The blots were developed by 
autoradiography using an ECL-Western blotting system 
(Amersham International, Buckinghamshire, UK). The 
immunoblots of cardiac troponin I (28  kDa) and phos-
photroponin I (28  kDa) were quantified using a laser 
densitometer.
Small interfering RNA (siRNA) transfection assay
Double-stranded siRNA sequences targeting STAT3 
mRNA were obtained from Sigma Biotechnology. The 
cells were cultured in 100-mm-well plates in medium. 
Transfection with siRNA was carried out with transfec-
tion reagent (PureFection™; System Biosciences, Moun-
tain View, CA, USA). Specific silencing was confirmed 
by immunoblotting with cellular extracts after the 
transfection.
Reverse transcription polymerase chain reaction (RT–PCR)
Total RNA of rat LV was isolated following the protocol 
described previously. Two hundred nanograms of total 
RNA was reverse transcribed into cDNA with random 
hexamer primers (Roche Diagnostics, Mannheim, Ger-
many). The PPARδ gene expression was measured using 
RT–PCR. Expression of hydroxymethylbilane synthase 
(HMBS), a housekeeping gene, was analyzed for nor-
malization and quality control. We used the following 
primers: PPARδ forward 5′-aagacaaacccacggtaaagg-3′ 
and reverse 5′-catgactgacccccacttg-3′, MMP9 forward 
5′-tcgtggctctaaacctgacc-3′ and reverse 5′-gagctgtcggc 
tgtggtt-3′, CTGF forward 5′-atgctgtgaggagtgggtgt-3′ and 
reverse 5′-ggccaaatgtgtcttccagt-3′, and HMBS forward 
5′-tgccctggagaagaatgaag-3′, and reverse 5′-cagcatcat-
gagggttttcc-3′. PCR amplification of these genes was car-
ried out with 20 ng cDNA, 200 nM forward and reverse 
primers, and TaqMan Master Mix (Roche Diagnostics) 
in a final volume of 10 μL. PCRs were run in a Light-
Cycler 2.0 (Roche Diagnostics) for 45 cycles, with each 
cycle consisting of denaturation for 15 s at 95 °C, primer 
annealing for 15  s at 55  °C, extension for 30  s at 72  °C, 
and cooling 30 s at 40 °C.
Statistical analysis
Differences among normal control subjects and diabetic 
patients before and after telmisartan treatment were 
compared using Student’s t tests for normally distributed 
continuous variables, nonparametric tests for non-nor-
mally distributed continuous variables, and χ2 tests for 
categorical variables. Group differences were analyzed 
using analysis of variance. Factors with p < 0.1 based on 
the univariate analyses were included in the multivariate 
logistic regression analyses. A p  <  0.05 was considered 
significant. All analyses were performed using SPSS ver-
sion 18 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Telmisartan improved cardiac remodeling in diabetic 
patients
Among the control group and diabetic patients before 
and after telmisartan treatment, no significant differ-
ences in clinical characteristics were observed except for 
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blood glucose and hemoglobin A1c. All diabetic patients 
received one or two types of oral antidiabetic agents 
(Table  1). There were no differences in blood pressure, 
LVEF, or E/A (Table  2). However, compared with nor-
mal control subjects, the mean peak systolic strains in 
the longitudinal and circumferential directions (Fig.  1) 
and tissue Doppler-derived e′ were more impaired in 
the patients with diabetes. Furthermore, after 3 months 
of telmisartan treatment, the mean peak systolic strains 
in both the longitudinal and circumferential directions 
improved compared with baseline values.
Telmisartan decreased diabetes‑induced cardiac fibrosis 
in STZ rats through the PPARδ pathway
Masson trichrome staining revealed a significant increase 
of fibrotic intensity in the STZ-induced diabetic rat hearts 
compared with the control hearts. Notably, the cardiac 
fibrosis in the diabetic rats ameliorated significantly post 
treatment with telmisartan but not under the treatment 
of metformin, an AMP-activated protein kinase (AMPK) 
pathway activator. Conversely, additional treatment with 
the PPARδ antagonist GSK0660 diminished the improve-
ment (Fig.  2a). Telmisartan reversed the STZ-induced 
downregulation of PPARδ. Compared with the control 
rats, the expression of PPARδ was significantly attenu-
ated in the STZ-treated rat hearts but increased after the 
telmisartan treatment. Notably, once PPARδ was blocked 
by GSK0660, the effect was extinguished. Notably, the 
fibrosis-associated proteins, including CTGF, MMP9, 
and STAT3, were significantly upregulated in STZ-
treated rat hearts but decreased under the treatment of 
telmisartan via the PPARδ pathway (Fig.  2b). Likewise, 
a similar finding was observed regarding the relative 
expression of PPARδ and the downstream proteins using 
RT–PCR (Fig. 2c).
Effect of PPARδ on cardiac fibrosis in high‑glucose–treated 
cardiomyocytes
After incubation with 30  mM glucose, rat cardiomyo-
cytes showed a significant downregulation of PPARδ. 
Consequently, the expression of fibrosis-associated pro-
teins, including STAT3, CTGF, and MMP9, increased. 
Nevertheless, co-treatment with GW0742, a PPARδ 
agonist, partially rescued the downregulation of PPARδ 
and additionally attenuated the upregulation of STAT3, 
CTGF, and MMP9. Notably, without the condition of 
hyperglycemia, GW0742 failed to increase the expression 
of PPARδ or to affect the subsequent fibrosis-associated 
proteins (Fig. 3).
The interplay between PPARδ and STAT3 with respect 
to cardiac fibrosis
Alternatively, the overexpression of STAT3 in cardio-
myocytes resulted in a significant downregulation of 
PPARδ (Fig.  4a). Co-treatment with GW0742 was suf-
ficient to reactivate PPARδ, but the effect was attenu-
ated by the PPARδ inhibitor GSK0660. Conversely, the 
upregulation of STAT3 induced by high glucose was 
decreased by treatment with Stattic, a small-molecule 
inhibitor of STAT3 dimerization (Fig.  4b). Instead, of 
external inhibition of STAT3, internal knockdown of 
STAT3 by siRNA also directly reversed the hypergly-
cemia-related high expression of CTGF, STAT3, and 
MMP9 (Fig. 4c, d).
Table 1 Clinical characteristics of  the normal control and  diabetic patients before  and after  3  months of  telmisartan 
treatment
Data are expressed as mean ± standard deviation or median (interquartile range). Italic values indicate significance
HbA1c hemoglobin A1c
Normal control (n = 10) Baseline (n = 15) After telmisartan (n = 15) p value
Age (years) 52.2 ± 8.5 55.3 ± 8.8 – 0.25
Male (%) 6 (60) 11 (73.3) – 0.12
Body height (cm) 165.8 ± 7.4 163.9 ± 8.7 – 0.72
Body weight (kg) 68.6 ± 7.1 70.8 ± 10.6 – 0.81
Heart rate (beats/min) 69.8 ± 7.6 73.5 ± 8.24 72.38 ± 11.74 0.64
Systolic blood pressure (mmHg) 120.2 ± 12.9 129.6 ± 17.1 122.1 ± 14.4 0.06
Diastolic blood pressure (mmHg) 83 ± 8.9 82.6 ± 7.7 85.2 ± 13.9 0.43
Preprandial serum glucose (mg/dL) 92.7 ± 5.6 122 ± 15.8 105.3 ± 10.6 0.01
HbA1c (%) 5.6 ± 0.9 7.8 ± 1.2 7.2 ± 0.8 0.02
Creatinine clearance rate (ml/min) 108.7 ± 45.8 83.7 ± 24.5 95.8 ± 24.6 0.29
Triglyceride (mg/dL) 122.6 ± 51.3 129 ± 6.2 – 0.59
Cholesterol (mg/dl) 178.7 ± 28.8 178.6 ± 32.3 – 0.67
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Discussion
In the present study, we found that (1) telmisartan 
improved cardiac remodeling in patients with diabetes; 
(2) the development of cardiac fibrosis in the diabetic 
rat was markedly decreased after telmisartan treatment 
through the PPARδ pathway; (3) the regulatory mecha-
nism of PPARδ on the hyperglycemia-induced fibrosis 
was dependent on the activation of STAT3. To the best 
of our knowledge, this is the first multidisciplinary study 
coordinating the clinical imaging, histologic evidence, 
and molecular mechanisms to investigate the therapeu-
tic potentials of a new target, PPARδ, in protection from 
diabetes-induced cardiac fibrosis.
Diabetes‑related cardiac fibrosis
Diabetes has emerged as a major threat to worldwide 
health, and the incidence continues to increase each 
year [1]. The importance of diabetic cardiomyopathy, i.e., 
Table 2 Conventional and  speckle-tracking echocardiographic parameters of  normal control and  diabetic patients 
before and after 3 months of telmisartan treatment
Data are expressed as mean ± standard deviation. Italics indicate significance
LVMI left ventricular mass index, LVIDd left ventricular interior dimension at end diastole, LVEF left ventricular ejection fraction, IVRT isovolumic relaxation time, 
DT deceleration time, E/A transmitral valve E to A velocity ratio, E/eʹ mitral early filling velocity to early diastolic mitral annular velocity ratio, MPI myocardial 
performance index, GLS peak systolic global longitudinal strain, GCS peak systolic global circumferential strain
Normal control (n = 10) Baseline (n = 15) After telmisartan (n = 15) p value
LVMI (g/m2) 83.3 ± 29.1 84.5 ± 29.8 85.1 ± 30.2 0.63
LVIDd (cm) 4.2 ± 0.8 4.1 ± 0.7 4.1 ± 1.4 0.52
LVEF (%) 70.5 ± 6.4 68.1 ± 4.5 69.3 ± 15.7 0.38
E (cm/s) 76.5 ± 18.3 79.5 ± 12.3 82.7 ± 18.3 0.72
E/A 1.0 ± 0.3 1.0 ± 0.2 0.9 ± 0.6 0.06
e′ (cm/s) 10.3 ± 2.8 8.2 ± 1.8 9.3 ± 2.7 0.01
IVRT (ms) 94.7 ± 23 96.6 ± 13.1 90.7 ± 21.5 0.06
DT (ms) 200.5 ± 58.6 184.1 ± 52.2 198.4 ± 43.7 0.93
MPI 0.4 ± 0.2 0.5 ± 0.1 0.5 ± 0.1 0.35
GLS (%) −20.2 ± 6.7 −16.4 ± 5.2 −18.1 ± 6.2 0.03
GCS (%) −22.2 ± 7.8 −14.7 ± 8.6 −20.8 ± 6.8 0.01
Fig. 1 An illustration of speckle‑tracking imaging analysis in diabetic patients. a The longitudinal and b circumferential strains in diabetic patients 
before telmisartan treatment. c, d The improvement of longitudinal c and circumferential (d) strains in diabetic patients after telmisartan treatment. 
GLS systolic global longitudinal strain, GCS systolic global circumferential strain
Page 6 of 9Chang et al. Cardiovasc Diabetol  (2016) 15:113 
congestive heart failure in diabetic patients in the absence 
of discernible coronary artery disease (valvular disease 
or hypertension), has received more attention in recent 
decades [1]. Diabetic cardiomyopathy is characterized 
by myocyte loss and myocardial fibrosis, leading to 
decreased elasticity and impaired contractile function 
[1, 20]. Regarding its pathophysiology, the main theory 
focused on the accumulation of extracellular matrix 
Fig. 2 Telmisartan decreased diabetes‑induced cardiac fibrosis in STZ rats via PPARδ. a Hematoxylin and eosin and Masson trichrome staining of 
control (Sham) rat hearts, STZ‑treated rat hearts, and STZ‑treated rat hearts treated with telmisartan, telmisartan plus GSK0660 (a PPARδ antagonist), 
or metformin. b The expression of PPARδ, STAT3, CTGF, and MMP9 proteins in the variously treated rat hearts. c The relative expression of PPARδ, 
STAT3, CTGF, and MMP9 in variously treated rat hearts. STZ streptozotocin, Tel telmisartan, PPARδ peroxisome proliferator‑activated receptor δ, 
STAT3 signal transducer and activator of transcription 3, CTGF connective tissue growth factor, MMP9 matrix metallopeptidase 9
Fig. 3 Expression of fibrosis‑associated proteins in cardiomyocytes Cardiomyocytes in hypoglycemic conditions were treated with GW0742 (a 
PPARδ agonist). a PPARδ; b STAT3; c CTGF; and d MMP9. PPARδ peroxisome proliferator‑activated receptor δ, STAT3 signal transducer and activator of 
transcription 3, CTGF connective tissue growth factor, MMP9 matrix metallopeptidase 9
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proteins [1, 21]. Among them, MMP9 and CTGF are cru-
cial in virtually all diabetes-induced fibrotic pathology, 
including nephritic, retinal, and cardiac fibrosis [21, 22]. 
In addition, the conversion of energy catabolism in mito-
chondria and the subsequent ROS production were also 
proposed to contribute to the structural and functional 
abnormalities [22, 23]. However, the direct regulator of 
the development of diabetic cardiomyopathy remains 
unknown.
The role of telmisartan in cardiac remodeling
To detect myocardial dysfunction at an early stage, 
instead of histological evidence, imaging, such as STE, 
can be used to unmask subtle changes in the cardiac 
function of patients with systemic conditions such as 
cancer or diabetes mellitus [3]. In a previous study using 
STE, telmisartan was found to have beneficial effects on 
LV structure and function in patients with hypertension 
[7, 8]. Notably, telmisartan shows not only antihyperten-
sive but also several pleiotropic effects that interact with 
metabolic pathways to ameliorate cardiac remodeling 
by activating PPARs [4]. In the work of Mikami and col-
leagues, telmisartan activated endogenous PPARδ and 
played an antifibrotic role in human mesangial cells [24]. 
In skeletal muscle, telmisartan was shown to enhance 
running endurance through activation of the PPARδ 
pathway [25]. More specifically, using PPARδ knockout 
mice, the effect of telmisartan on insulin signaling and 
glucose uptake was validated to involve PPARδ or phos-
phatidylinositol-3 kinase but not PPARγ and PPARα [26, 
27]. In our study, the cardiac fibrosis in the diabetic rats 
was significantly ameliorated by telmisartan but not met-
formin, an AMPK pathway activator [28]. By blocking 
PPAR-δ, the telmisartan-related improvement of cardiac 
fibrosis was extinguished, and consequently, the down-
stream fibrosis-associated proteins were significantly 
reactivated [26]. Taken together, telmisartan reversed 
the hyperglycemia-induced cardiac fibrosis through the 
PPARδ pathway instead of the AMPK pathway. Interest-
ingly, our study also indicated that enhancing the expres-
sion of PPARδ attenuated the upregulation of subsequent 
fibrosis-associated proteins in cardiomyocytes in hyper-
glycemic conditions. This result implied that the effect of 
PPARδ on the cardiomyocytes may be independent from 
telmisartan.
The effects of PPARδ on hearts
PPARδ has emerged as a versatile regulator of metabolic 
and inflammatory homeostasis [13, 14, 29]. Deletion of 
cardiac PPAR-δ is accompanied by decreased contrac-
tion, lowered cardiac output, and decreased contraction, 
which leads to cardiac failure [13]. In our previous study, 
we also demonstrated that activation of PPARδ using the 
selective agonist GW0742 enhanced cardiac contractility 
in isolated hearts and the hemodynamics in rats with-
out altering heart rate [14]. Regarding the mechanism of 
how PPARδ ameliorates cardiac fibrosis, a previous study 
indicated that the PPARβ/δ agonist inhibited STAT3 acti-
vation and insulin resistance in human liver cells [17]. 
Likewise, activation of PPARβ/δ ameliorated insulin sign-
aling by inhibiting STAT3 in interleukin-6-stimulated 
adipocytes [26]. In the work of Serrano-Marco and col-
leagues, activation of PPARβ/δ with an agonist prevented 
induction of the transcription factor STAT3, which 
results in the prevention of insulin resistance in adipose 
tissue [18]. Nevertheless, the details remain unknown.
STAT3 is fundamental for physiological homeostasis 
and is involved in multiple post-translational modi-
fications, including proliferation, differentiation, and 
metabolism in cardiomyocytes, fibroblasts, and vari-
ous inflammatory cells [30]. Downregulation of STAT3 
is sufficient to induce dilated and adverse remodeling 
Fig. 4 Protein expression of PPARδ and STAT3 in cardiomyocytes. a Protein expression of PPARδ in STAT3‑overexpressing cardiomyocytes treated 
with GW0742 or GSK0660. b Protein expression of STAT3 in cardiomyocytes treated with Stattic, an inhibitor of STAT3 under hyperglycemic condi‑
tions. c Downregulation of STAT3 in cardiomyocytes treated with si‑STAT3. d Protein expression of STAT3 in the STAT3 knockdown cardiomyocytes 
in high‑glucose conditions. PPARδ peroxisome proliferator‑activated receptor δ, STAT3 signal transducer and activator of transcription 3, si small 
interfering
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after myocardial infarction [30, 31]. However, overex-
pression of STAT3 also results in cardiac hypertrophy 
[32]. Interestingly, STAT3 also contributes to insulin 
resistance and glucose homeostasis [33]. Inhibition 
of mammalian target of rapamycin was found to pro-
tect against reperfusion injury in the diabetic heart 
through STAT3 signaling [30, 34]. In agreement with 
our findings, losartan, also an ARB, reduced myo-
cardial interstitial fibrosis in diabetic cardiomyopa-
thy rats by inhibiting the Janus kinase/STAT signaling 
pathway [4]. However, in contrast to above finding, we 
found that the overexpression of STAT3 directly down-
regulated PPARδ independent from the stimulation of 
hyperglycemia [31]. This result implied the importance 
of STAT3 in myocardial fibrosis and its potential role 
in homeostasis along with PPARδ. To conclude, tel-
misartan works through PPARδ, instead of the AMPK 
pathway, to suppress the hyperglycemia-enhanced 
expression of STAT3/CTGF/MMP9 and the subse-
quent cardiac fibrosis (Graphic abstract).
There are some limitations of this study. First, Tel-
misartan works not only in PPARδ but PPAR gamma 
[35–39]. However,  PPARγ activator, like Thiazolidin-
ediones, is associated with side effects such as edema 
and body weight gain [40]. Therefore, using a PPARδ 
specific ligand, GW0742, can activate the protective 
effects from hypertriglyceridemia and insulin resist-
ance as what PPARα and PPARγ do but alternatively 
prevents the sequel of edema and fluid retention 
induced by PPARγ [14, 18]. Therefore, we suggested 
using a PPARδ specific ligand instead of telmisartan 
in the future clinical studies. Second, according to our 
findings, it is concluded that the myocardium protec-
tive effect of PPARδ in diabetic cardiomyopathy is reg-
ulated by STAT3 and we believed that it is indirectly 
through ROS reduction. As we know, ROS plays an 
integral role in dys-regulation of diabetic myocardium 
remodeling and notably, a number of anti-oxidant and 
antiapoptotic genes are upregulated by STAT3 [41]. In 
another aspect, agonist-activated PPARδ suppressed 
the generation of Angiotensin II-triggered ROS with a 
concomitant reduction in DNA damage [6, 17]. Taken 
together, ROS is believed to be involved in the rela-
tionship between PPARδ and STAT3 and we will focus 
on it in the future studies.
Conclusion
These results indicate that telmisartan activates endog-
enous PPARδ and may prevent CTGF/MMP9-induced 
fibrotic changes by upregulating STAT3 expression in a 
hyperglycemic environment. These findings potentially 
elucidate the beneficial effects of telmisartan on LV struc-
tural and functional restoration.
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